Under separate agreements that are in the process of being negotiated by both companies, ROVI will receive exclusive licenses to Novavax's portable VLP vaccine technology to commercialize flu vaccines in Spain and Portugal, and non-exclusive licenses in Europe, Latin America and Africa.
Rahul Singhvi, President and Chief Executive Officer of Novavax, stated: "We are honored to be selected by the Spanish Health Ministry and ROVI Pharmaceuticals to help develop pandemic and seasonal flu vaccine solutions for Spain, the world's eighth largest economy with more than 43 million people.
Today's contemplated partnership with ROVI and the Spanish government will enable funding to support development and registration of VLP-based influenza vaccines in the European Union and possibly other countries, including the United States.
Juan Lopez-Belmonte Encina, ROVI CEO, commented: "The pandemic flu vaccine business is currently a key part of the strategy of ROVI, and we are committed to the business as one of the future growth drivers for the company.
All ROVI carrier systems are manufactured under pharma-GMP conditions.
ROVI is represented through a network of distributors worldwide.
In 2008 ROVI is going to launch new state-of-the-art carrier system technologies.
com has completed their technical analysis on BBRY, AOL, ROVI, and EGHT and these free reports are accessible by registering at:
Sign up and read the complimentary report on ROVI at: